News

Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming ...
Gilead's FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over ...
The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...
The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...
The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move ...
HIV and global health activists say the deployment of Gilead’s twice-a-year HIV prevention shot is the world’s best chance to ...
Lenacapavir, the world's first twice-yearly HIV prevention shot, gets US FDA nod-offering a discreet, long-acting solution ...
The United States Food and Drug Administration (FDA) has approved long-acting injectable lenacapavir for HIV prevention. The ...
FRIDAY, June 20, 2025 (HealthDay News) — A new shot to prevent HIV infection has just been approved — and it only needs to be ...
The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported ...
The U.S. Food and Drug Administration has approved a new HIV prevention medication that's been found to be highly effective.
The new HIV PrEP option could drastically reduce the number of new cases by offering a new alternative to daily pills or every-other-month injections.